Guobang Pharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Guobang Pharma has a total shareholder equity of CN¥7.8B and total debt of CN¥909.1M, which brings its debt-to-equity ratio to 11.6%. Its total assets and total liabilities are CN¥10.6B and CN¥2.8B respectively. Guobang Pharma's EBIT is CN¥811.7M making its interest coverage ratio -28. It has cash and short-term investments of CN¥2.2B.
Anahtar bilgiler
11.6%
Borç/özkaynak oranı
CN¥909.09m
Borç
| Faiz karşılama oranı | -28x |
| Nakit | CN¥2.16b |
| Eşitlik | CN¥7.85b |
| Toplam yükümlülükler | CN¥2.79b |
| Toplam varlıklar | CN¥10.63b |
Son finansal sağlık güncellemeleri
These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24
We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25Recent updates
Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)
Aug 26These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially
May 21Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)
Apr 18We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 605507's short term assets (CN¥5.7B) exceed its short term liabilities (CN¥2.6B).
Uzun Vadeli Yükümlülükler: 605507's short term assets (CN¥5.7B) exceed its long term liabilities (CN¥224.7M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 605507 has more cash than its total debt.
Borcun Azaltılması: 605507's debt to equity ratio has reduced from 34.4% to 11.6% over the past 5 years.
Borç Kapsamı: 605507's debt is well covered by operating cash flow (59.3%).
Faiz Kapsamı: 605507 earns more interest than it pays, so coverage of interest payments is not a concern.